Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights
This Phase 3 trial demonstrates that pegylated liposomal doxorubicin significantly extends progression-free survival and improves response rates in patients with advanced desmoid tumors, offering a potent systemic option for refractory disease.